UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

NOVO NORDISK A/S,

Patent Owner.

Case No. IPR2023-00724

Patent No. 10,335,462

DECLARATION OF WILLIAM J. JUSKO, PH.D., IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 10,335,462

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS

Page

I. QUALIFICATIONS AND BACKGROUND 9

A. EDUCATION AND EXPERIENCE 9

B. PRIOR TESTIMONY 13

C. BASIS FOR OPINIONS AND MATERIALS CONSIDERED 14

D. RETENTION AND COMPENSATION 14

II. LEGAL STANDARDS 14

III. PERSON OF ORDINARY SKILL IN THE ART 17

IV. BRIEF SUMMARY OF OPINIONS 18

V. THE '462 PATENT [EX. 1001] 19

A. THE SPECIFICATION AND CLAIMS OF THE '462 PATENT 19

B. THE PROSECUTION HISTORY OF THE '462 PATENT 21

VI. CLAIM CONSTRUCTION 24

VII. BACKGROUND 26

A. PHARMACOKINETICS AND PHARMACODYNAMICS 26

B. DRUG DEVELOPMENT - CLINICAL TRIAL DESIGN 29

C. PHARMACOKINETICS AND PHARMACODYNAMICS RELATED TO GLP-1 AND SEMAGLUTIDE 36

1. GLP-1 36

2. GLP-1 derivatives 37

D. SEMAGLUTIDE CLINICAL TRIALS 45

VIII. SCOPE AND CONTENT OF THE PRIOR ART 49

A. WO421 [EX. 1011] 50

B. LOVSHIN [EX. 1012] 52

C. WO537 [EX. 1015] 54

D. SEMAGLUTIDE CLINICAL TRIALS 56

1. NCT657 [Ex. 1013] 56

2. NCT773 [Ex. 1014] 58

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS
(continued)

Page

3. Public Availability of ClinicalTrials.gov 60

E. KNUDSEN 2004 [EX. 1032] 67

F. LUND [EX. 1035] 67

G. SEINO [EX. 1038] 71

H. VICTOZA LABEL [EX. 1039] 73

I. SHARGEL [EX. 1045] 75

J. TAMIMI [EX. 1047] 77

K. FDA EXPOSURE RESPONSE 2003 [EX. 1048] 79

L. ICH 1994 [EX. 1049] 80

M. KNUDSEN 2010B [EX. 1066] 83

N. ADDITIONAL PRIOR ART AND REFERENCES 84

IX. UNPATENTABILITY OF THE '462 PATENT 84

A. GROUND 1: WO421 ANTICIPATED CLAIMS 1-3 OF THE '462 PATENT 84

1. Teachings of WO421 84

2. WO421 anticipated claim 1 84

3. WO421 anticipated claim 2 90

4. WO421 anticipated claim 3 90

B. GROUND 2: LOVSHIN ANTICIPATED CLAIMS 1-3 OF THE '462 PATENT 91

1. Teachings of Lovshin 91

2. Lovshin anticipated claim 1 91

3. Lovshin anticipated claim 2 94

4. Lovshin anticipated claim 3 95

C. GROUND 3: CLAIMS 1-10 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS OVER WO421 95

1. Claim 1 would have been obvious over WO '421 95

2. Claim 2 would have been obvious over WO '421 104

3. Claim 3 would have been obvious over WO '421 104

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS
(continued)

Page

4. Claims 4-10 would have been obvious over WO '421 considering the '424 publication 105

D. GROUND 4: CLAIMS 1-10 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS OVER WO537 CONSIDERING LOVSHIN 105

1. Claim 1 would have been obvious over WO537 considering Lovshin 105

2. Claim 2 would have been obvious over WO537 considering Lovshin 114

3. Claim 3 would have been obvious over WO537 considering Lovshin 114

4. Claims 4-10 would have been obvious over WO537 considering Lovshin 115

E. GROUND 5: CLAIMS 1-10 OF THE '462 PATENT WOULD HAVE BEEN OBVIOUS OVER NCT657 AND NCT773 116

1. Claim 1 would have been obvious over NCT657 and NCT773 116

2. Claim 2 would have been obvious over NCT657 and NCT773 124

3. Claim 3 would have been obvious over NCT657 and NCT773 124

4. Claims 4-10 would have been obvious over NCT657, NCT773, and the '424 publication 125

F. NO SECONDARY CONSIDERATIONS OVERCOME *PRIMA FACIE* OBVIOUSNESS OF THE CLAIMED ALLEGED INVENTIONS 126

1. No unexpected results 126

2. No long-felt, unmet need or skepticism 126

X. CONCLUSION 127

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF ABBREVIATIONS

Full Name of Cited Reference	Abbreviation
U.S. Patent App. Pub. No. 2011/0166321	'321 publication
U.S. Patent App. Pub. No. US2007/0010424	'424 publication
U.S. Patent No. 10,335,462	'462 patent
U.S. Patent App. Pub. No. 2004/0102486	'486 publication
U.S. Patent No. 5,512,549	'549 patent
Bell, *Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides*, 302 NATURE 716 (1983)	Bell
Blonde, *Comparison of Liraglutide Versus Other Incretin-Related Anti-Hyperglycaemic Agents*, 14 (suppl. 2) DIABETES, OBESITY & METABOLISM 20 (2012)	Blonde
Drab, *Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects*, 30 PHARMACOTHERAPY 609 (2010)	Drab
FDA Guidance for Industry, *Exposure-Response Relationships - Study Design, Data, Analysis, and Regulatory Applications* (Apr. 2003)	FDA Exposure Response 2003
Garber, *Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-Controlled, Dose-Response Trial*, 102 AM. J. MED. 491 (1997)	Garber
Holst, *Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from the Distal Gut*, 211 (2) FEBS LETTERS 169 (1987)	Holst
International Conference on Harmonisation; Dose-Response Information to Support Drug Registration; Guideline; Availability, 59 Fed. Reg. 55972 (Nov. 9, 1994)	ICH 1994
Kirillova, *Results and Outcome Reporting in ClinicalTrials.gov, What Makes it Happen?*, 7(6) PLOS ONE 1 (2012)	Kirillova

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.